文献速递头颈外科

揭示处方模式:头颈癌术后慢性阿片类药物处方的系统综述

Unveiling Prescribing Patterns: A Systematic Review of Chronic Opioid Prescriptions After Head and Neck Cancer Surgeries.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-02-17

本系统综述检索MEDLINE、Embase和CENTRAL(1998至2023年),纳入24项研究共17,027例来自美国、中国和加拿大的头颈癌大手术后患者,评估阿片类药物处方模式。术后持续阿片类药物使用(治疗后90天仍在处方)比例为15.4%至64%,两项研究报告不良事件发生率高达16%。作者认为需根据个体风险因素定制疼痛管理并关注多模式镇痛,未来需前瞻性研究确定最佳策略。

要点

  • 头颈癌大手术后持续阿片类药物使用(术后90天)比例为15.4%至64%。
  • 慢性使用风险因素包括术前阿片使用、吸烟、较高癌症分期、辅助治疗及人口学因素。
  • 两项研究报告不良事件,高达16%患者出现副作用;患者报告疼痛控制差异显著。

核心结论

  • 头颈癌术后持续阿片类药物使用常见,疗效不一且存在不良反应风险。
  • 作者认为根据个体风险因素定制疼痛管理并关注多模式镇痛可降低持续阿片使用的风险。
  • 未来需前瞻性研究以确定最佳疼痛管理策略。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase和CENTRAL,覆盖1998年至2023年。
  • 纳入评估头颈癌大手术后阿片处方模式的研究,场景包括三级医院和社区医院。
  • 共纳入24项研究,涉及17,027例来自美国、中国和加拿大的患者。
  • 使用MINORS量表评估质量,非比较研究平均得分9.9,比较研究平均得分20.0。

主要发现

  • 术后持续阿片使用(治疗后90天仍在处方)比例为15.4%至64%。
  • 两项研究报告不良事件,高达16%的患者出现副作用。
  • 慢性使用风险因素包括术前阿片使用、吸烟、较高癌症分期、辅助治疗及人口学因素。
  • 较大阿片处方与晚期癌症较短生存之间存在相关性。
  • 患者报告的疼痛控制存在显著差异。

临床怎么用

  • 作者认为根据个体风险因素定制疼痛管理并关注多模式镇痛可降低持续阿片使用的风险。
  • 未来需前瞻性研究以确定最佳疼痛管理策略。

局限性

  • 未来需前瞻性研究以确定最佳疼痛管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to review opioid prescribing changes for pain management in head and neck cancer (HNC) surgery patients, given the recent focus on Enhanced Recovery After Surgery protocols. DATA SOURCES: MEDLINE, Embase, and CENTRAL, covering 1998 to 2023. REVIEW METHODS: We selected studies that evaluated opioid prescribing patterns post-major HNC surgery in various settings, including tertiary care hospitals and community hospitals. Primary outcomes considered were prevalence and patterns of opioid use post-surgery, as well as related outcomes such as chronic use and side effects. RESULTS: Of 1278 abstracts, 24 studies involving 17,027 patients from the United States, China, and Canada met inclusion criteria. Quality was assessed using the MINORS scale, with an average score of 9.9 for non-comparative studies and 20.0 for comparative studies. Persistent opioid use post-surgery, defined as ongoing prescriptions 90 days after treatment, was noted in 15.4% to 64% of patients. Two studies reported adverse events, with up to 16% of patients experiencing side effects. Risk factors for chronic use included preoperative opioid use, tobacco use, higher cancer stage, adjuvant treatment, and demographic factors. Correlations were found between larger opioid prescriptions and shorter survival in advanced cancers. There was notable variability in patient-reported pain control. CONCLUSION: Persistent opioid use post-HNC surgery is common, with variable efficacy and risk of adverse effects. Tailoring pain management to individual risk factors and focusing on multimodal analgesia could reduce the risks of continued opioid use. Future prospective studies are required to identify optimal pain management strategies.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Karki S, Stephanian B, Ramirez M, et al. Unveiling Prescribing Patterns: A Systematic Review of Chronic Opioid Prescriptions After Head and Neck Cancer Surgeries. Otolaryngol Head Neck Surg. 2025. PMID: 39960294. doi:10.1002/ohn.1165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。